The Phase 1 data are supportive but early-stage; they do not alter the near-term commercial outlook for vamorolone in DMD. Monitor for any subsequent regulatory filings or partnership announcements that could signal life-cycle expansion into new indications.
Drug in focus
CPRX drug pipeline →AGAMREE
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (US launch March 2024)
- Next catalyst
- None dated
What to watchFor a non-medical investor, AGAMREE is a commercial-stage asset already contributing meaningful revenue growth ($117M in 2025, guiding $140-150M for 2026). There's no binary FDA catalyst ahead, so the stock moves on quarterly sales execution and overall company performance. Watch quarterly AGAMREE revenue growth rates and any news about label expansion studies (DMD is the only approved indication). Multiple analysts downgraded CPRX to Hold/Neutral recently, suggesting the easy money from the approval catalyst is behind it.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Jul 1 $31.44entry
- T+1 · 5mo ago +0.03%α +0.16% · $31.45
- T+5 · 4mo ago +0.16%α −0.10% · $31.49
- T+20 · due 4mo ago Pending
- T+60 · due 8w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals announced topline results from a Phase 1 study of vamorolone (AGAMREE) showing balanced corticosteroid activity with glucocorticoid effects but without significant immunosuppression at clinical doses. The data support the drug's current DMD dosing and potential expansion into other chronic inflammatory rare diseases, though no near-term regulatory or financial impact is expected.
Key Facts
- Phase 1 study in healthy adults showed vamorolone and deflazacort had comparable cortisol suppression at clinical doses.
- Vamorolone demonstrated less pronounced immunosuppressive biomarker effects than deflazacort in Part A.
- In Part B, clinically relevant immunosuppression was observed only at the highest dose (40 mg/kg/day), which is above approved dosing.
- No relevant immunosuppressive effects were seen at lower doses (9 or 27 mg/kg/day).
- The data support vamorolone's potential utility across a broad range of chronic inflammatory rare diseases.
Financial Impact
No financial figures reported; the filing is a clinical data update with no immediate revenue or cost impact.
Risk Factors
- No guarantee that vamorolone will receive regulatory approval for additional indications.
- Competition from other corticosteroids and anti-inflammatory therapies could limit market opportunity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290768 |
| Document: d158010dex991.htm | 0001193125-26-290768 |
| Document: 0001193125-26-290768-index-headers.html | 0001193125-26-290768 |
| Document: 0001193125-26-290768-index.html | 0001193125-26-290768 |
| Document: 0001193125-26-290768.txt | 0001193125-26-290768 |
Track record
16 reports on CPRX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Viewing Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers